natgillin/translations-raw huggingface dataset:
Close bottle with child-resistant cap tightly.
Čvrsto zatvorite bocu pomoću poklopca zaštićenog od slučajnog odvrtanja.
close clinical follow-up should be undertaken measurement of liver enzymes (ASAT, ALAT, gamma GT and alkaline phosphatase) and bilirubin, should be performed at frequent intervals:
bolesnika treba pomno klinički pratiti redovito treba mjeriti razine jetrenih enzima (AST, ALT, GGT i alkalnu fosfatazu) i bilirubina:
Close clinical surveillance (looking for signs of bleeding or anaemia) is recommended throughout the treatment period, especially if risk factors are combined (see section 5.1).
Preporučuje se pažljiv klinički nadzor (praćenje znakova krvarenja ili anemije) tijekom liječenja, osobito u slučaju kombinacije rizičnih faktora (vidjeti dio 5.1).
Close clinical surveillance is recommended when dabigatran etexilate is combined with amiodarone and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Preporučuje se poman klinički nadzor kada se dabigatraneteksilat kombinira s amiodaronom te osobito u slučaju krvarenja, posebice za bolesnike koji imaju blago do umjereno oštećenje bubrega.
Close clinical surveillance is recommended when dabigatran etexilate is combined with quinidine and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Preporučuje se poman klinički nadzor kada se dabigatraneteksilat kombinira s kinidinom, posebice u slučaju krvarenja, osobito u bolesnika koji imaju blago do umjereno oštećenje bubrega.
Close clinical surveillance is recommended when dabigatran etexilate is combined with verapamil and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Preporučuje se pažljiv kinički nadzor kada se dabigataneteksilat kombinira s verapamilom, a osobito pri pojavi krvarenja, posebice u slučajevima bolesnika s blagim do umjerenim oštećenjem bubrega.
Close clinical surveillance is recommended when dabigatran etexilate is combined with verapamil and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Preporučuje se poman klinički nadzor kada se dabigatraneteksilat kombinira s verapamilom, osobito u slučaju krvarenja, posebice u bolesnika s blagim do umjerenim oštećenjem bubrega.
Close contact with infants and pregnant women should be restricted during the initial 24 hours following the injection.
Potrebno je izbjegavati bliski kontakt s djecom i trudnicama tijekom prvih 24 sata nakon injekcije.
Close contact with infants and pregnant women should be restricted during the initial 24 hours following the injection.
Treba ograničiti blizak kontakt s dojenčadi i trudnicama tijekom prvih 24 sata nakon injekcije.
Close contacts who are pregnant or immunocompromised should not change the patient’s dressing or clean their injection site.
Osobe iz neposredne blizine koje su imunokompromitirane ili su trudnice ne smiju mijenjati bolesnikove zavoje ili čistiti njegovo mjesto injiciranja.
Close metabolic monitoring is recommended during the transition and in the initial weeks thereafter.
Tijekom prijelaza i u prvim tjednima nakon toga preporučuje se pomno nadzirati metabolizam.
Close monitoring for
Preporučuje se pažljivo
Close monitoring for
rifabutinom trebala bi se
Close monitoring for an effect on the QTc interval is advisable and a baseline ECG is recommended prior to initiating therapy with Tasigna and as clinically indicated.
Savjetuje se stalno praćenje utjecaja na QT interval te se preporučuje učiniti bazični EKG prije početka liječenja Tasignom, kao i kada je klinički indicirano.
Close monitoring for clinical signs and symptoms of CHF should be performed, especially in patients with cardiac risk factors and/or history of coronary artery disease.
Potreban je poman nadzor kako bi se uočili klinički znakovi i simptomi kongestivnog zatajivanja srca, osobito u bolesnika s kardijalnim faktorima rizika i/ili bolešću koronarnih arterija u anamnezi.
Close monitoring for signs of rilpivirine toxicity and possibly also dose adjustment of rilpivirine is
Preporučuje se pažljivo praćenje znakova toksičnosti rilpivirina kao i mogućnost prilagodbe doze rilpivirina kod istodobne primjene s Aptivusom/ritonavirom.
Close monitoring for signs of rilpivirine toxicity and possibly also dose adjustment of rilpivirine is recommended when co- administered with Aptivus/ritonavir.
Preporučuje se pažljivo praćenje znakova toksičnosti rilpivirina kao i mogućnost prilagodbe doze rilpivirina kod istodobne primjene s Aptivusom/ritonavirom.
Close monitoring is
terapijsko praćenje lijeka
Close monitoring is recommended if this medicinal product is administered with Daklinza in combination with sofosbuvir (see sections 4.4 and 4.8).
Preporučuje se pažljivo praćenje, ako se ovaj lijek primjenjuje s lijekom Daklinza u kombinaciji sa sofosbuvirom (vidjeti dijelove 4.4. i 4.8.)
Close monitoring is recommended if this medicinal product is administered with Epclusa (see sections 4.4 and 4.8).
Preporučuje se pažljivo praćenje ako se ovaj lijek primjenjuje s lijekom Epclusa (vidjeti dijelove 4.4 i 4.8).
Close monitoring is recommended in patients with several of these risk factors.
Preporučuje se pažljivo nadzirati bolesnike s nekoliko od tih čimbenika rizika.
Close monitoring is required of any patients who develop liver enzyme elevation with appropriate dose adjustment or discontinuation.
Potrebno je pažljivo pratiti bolesnike u kojih dođe do porasta razine jetrenih enzima te prilagoditi dozu na odgovarajući način ili potpuno prekinuti terapiju.
Close monitoring is required with frequent or prolonged use.
Redovito praćenje potrebno je kod česte ili produljene primjene.
Close monitoring is therefore needed in patients treated with Aptivus, co-administered with low dose ritonavir (see section 4.4).
Stoga je potrebno pažljivo praćenje bolesnika liječenih Aptivusom s niskom dozom ritonavira (vidjeti dio 4.4).
Close monitoring of
Preporučuje se pomno praćenje
Close monitoring of antimalarial response is warranted when co-administering INTELENCE and artemether/lumefantrine as a significant decrease in exposure of artemether and its active metabolite, dihydroartemisinin, may result in decreased antimalarial efficacy.
Opravdano je pažljivo praćenje antimalarijskog odgovora kada se INTELENCE istodobno primjenjuje s artemeter/lumefantrinom jer značajno smanjenje izloženosti artemeteru i njegovom aktivnom metabolitu, dihidroartemisinunu, može rezultirati smanjenom antimalarijskom djelotvornošću.
Close monitoring of blood parameters is advised in these patients.
Kod ovih se bolesnika savjetuje strogo praćenje parametara krvne slike.
Close monitoring of blood parameters is advised in these patients.
Kod ovih se pacijenata savjetuje strogo bolesnika parametara krvne slike.
Close monitoring of immunosuppressant concentrations for at least 2 weeks (until stable concentrations are reached) is recommended when starting or stopping treatment with efavirenz.
Kod uvođenja ili prekida liječenja efavirenzom, preporučuje se pažljivo pratiti koncentracije imunosupresiva tijekom najmanje 2 tjedna (dok se postignu stabilne koncentracije).
Close monitoring of immunosuppressant concentrations for at least two weeks (until stable concentrations are reached) is recommended when starting or stopping treatment with Atripla.
Prilikom početka ili prekida terapije Atriplom preporučuje se pomno praćenje koncentracija imunosupresiva tijekom najmanje dva tjedna (dok se ne postignu stabilne koncentracije).
Close monitoring of renal function is required in these patients (see section 4.5).
Potrebno je pažljivo pratiti funkciju bubrega u tih bolesnika (vidjeti dio 4.5).
Close monitoring of the patient's virologic response should be excercised.
Treba pažljivo pratiti virološki odgovor bolesnika.
Close monitoring of the pregnancy and clinical manifestations of Gaucher disease is necessary for the individualization of dose according to the patient’s needs and therapeutic response.
Nužno je pažljivo praćenje trudnoće i kliničkih manifestacija Gaucherove bolesti radi određivanja individualnih doza lijeka u skladu s potrebama i terapijskim odgovorom bolesnice.
close monitoring of the safety of tipranavir and a monitoring of plasma concentrations of atazanavir are strongly encouraged (see section
pratiti sigurnost tipranavira i koncentracije atazanavira u plazmi (vidjeti dio 4.4).
Close one nostril by placing your finger against the side of your nose and insert the spray tip into the other nostril (approximately 1 cm).
Zatvorite jednu nosnicu položivši prst sa strane nosa i umetnite vrh spreja u drugu nosnicu (otprilike 1 cm).
Close one nostril by placing your finger against the side of your nose and insert the spray tip into the other nostril.
Zatvorite jednu nosnicu polaganjem prsta na bočnu stranu nosa i umetnite vrh spreja u drugu nosnicu.
Close soft tissues around the site containing the product using suture material of choice.
Materijalom po izboru zašijte meko tkivo oko kirurškog mjesta na koje ste nanijeli lijek.
Close supervision of high-risk patients should accompany antipsychotic therapy.
Visokorizični bolesnici moraju se strogo nadzirati uz terapiju antipsihoticima.
Close supervision of patients and in particular young adult patients and those at high risk should accompany therapy with naltrexone / bupropion especially in early treatment and following dose changes.
Pažljivi nadzor bolesnika, a posebno mladih odraslih bolesnika i onih s visokim rizikom, je potreban uz liječenje naltrekson / bupropionom, osobito u ranom liječenju i nakon promjena doze.
Close the bottle again
Ponovno zatvorite bocu
Close the bottle by screwing the cap back on tightly.
Zatvorite bocu tako što ćete na nju ponovno čvrsto staviti zatvarač.
Close the bottle cap firmly immediately after use
Bočicu čvrsto zatvorite odmah nakon primjene
Close the bottle cap firmly immediately after use
Dobro zatvorite zatvarač bočice nakon primjene.
Close the bottle cap firmly immediately after use.
Bočicu čvrsto zatvorite odmah nakon primjene.
Close the bottle cap firmly immediately after use.
Odmah nakon uporabe bočicu čvrsto zatvorite zatvaračem.
Close the bottle cap firmly immediately after use.
Čvrsto zatvorite bocu odmah nakon primjene.
Close the bottle cap firmly immediately after use.
Čvrsto zatvorite bočicu odmah nakon upotrebe.
Close the bottle tightly with the cap.
Zatvaračem čvrsto zatvorite bocu.
Close the bottle with the child safety bottle cap after each use.
Bocu zatvorite sigurnosnim zatvaračem za djecu nakon svake uporabe.
Close the bottle with the plastic screw cap after every usage.
Nakon svake upotrebe zatvorite bočicu plastičnim zatvaračem.
Close the bottle with the plastic screw cap.
Zatvorite bocu plastičnim navojnim zatvaračem.
Close the bottle, keep it safe
Zatvorite bocu i čuvajte je na sigurnom mjestu
Close the bottle.
Zatvorite bocu.
Close the inhaler
Zatvorite inhalator
Close the inhaler and replace the cap.
Zatvorite inhalator i vratite poklopac natrag.
Close the inhaler and rinse your mouth if possible
Zatvorite inhalator i po mogućnosti isperite usta
Close the inhaler until you hear a “click”.
Zatvorite inhalator tako da čujete „klik“.
Close the inhaler:
Zatvorite inhalator:
Close the jar and shake it carefully until all the powder is dissolved.
Pažljivo zatvorite posudicu i tresite je pažljivo dok se sav prašak ne otopi.
Close the label sealing the used patch within and discard, keeping out of reach of children.
Zalijepite naljepnicu kako biste zatvorili iskorišteni flaster u vrećicu i odložite ju izvan dohvata djece.
Close the lid and shake hard for at least 90 seconds until all the lumps have dissolved.
Zatvorite poklopac i dobro protresite tijekom najmanje 90 sekundi dok se grudice ne otope.
Close the lid to seal the mixing cup.
Zatvorite čašu za miješanje poklopcem.
Close the medicine reservoir by aligning the tabs of the medicine cap with the slots of the reservoir (a).
Zatvorite spremnik za lijek tako da poravnate oznake na poklopcu spremnika s urezima na samom spremniku (a).
Close the mouthpiece cover.
Zatvorite poklopac nastavka za usta
Close the tab on the reclosable bottle cap adapter.
Zatvorite čep nastavka za bocu za ponovno zatvaranje.
Close: Breathe out gently and close the mouthpiece cover
Zatvorite: Lagano izdahnite i zatvorite poklopac nastavka za usta
Close: Breathe out gently and close the mouthpiece cover.
Zatvorite: Lagano izdahnite i zatvorite poklopac nastavka za usta.
Closed pouches of fluid within the kidneys (kidney cysts).
zatvorene vrećice ispunjene tekućinom u bubrezima (bubrežne ciste).
Closed shoes: for feet.
Zatvorene cipele: za stopala.
closely for a decreased VPA
Zbog indukcije glukuronidacije lamotrigina
closely monitored for emergence of
radi nuspojava rifabutina.
closing of the throat, difficulty swallowing
zatvoreno grlo, otežano gutanje
Closing the potassium channel induces depolarisation of the beta cell and results – by opening of calcium channels – in an increased influx of calcium into the cell.
Zatvaranje kalijevih kanala izaziva depolarizaciju beta stanica i rezultira otvaranjem kalcijevih kanala te povećanim utokom kalcija u stanice.
Clostridium difficile associated diarrhoea
Proljev povezan s Clostridium difficile
Clostridium difficile colitis
kolitis uzrokovan Clostridium difficile
Clostridium difficile colitis; Mycobacterial infection (including tuberculosis); Epstein-Barr virus infection
uzrokovan Clostridium difficile, mikobakteri- jska infekcija (uključujući tuberkulozu), infekcija Epstein- Barrovim virusom
Clostridium difficile-associated diarrhoea
Dijareja povezana s Clostridium difficile
Clostridium difficile-associated diarrhoea (CDAD) has been reported with Cubicin (see section 4.8).
Tijekom primjene Cubicina prijavljen je proljev povezan s Clostridium difficile (vidjeti dio 4.8).
Clostridium difficile-associated diarrhoea**
Proljev povezan s Clostridium difficile
Clostridium difficile-associated disease
Bolest uzrokovana bakterijom Clostridium difficile
Clostridium perfringen
Clostridium perfringens,
Clostridium perfringens component:
Clostridium perfringens komponenta:
Clostridium perfringens, a bacterium which may be involved in the development of ERE, isolated from rabbits with ERE showed MIC90 values of 0.5 g/ml.
Clostridium perfringens, bakterija koja je možda uključena u razvoj epizootske zečje enteropatije (ERE), izolirana je iz kunića koji su imali ERE te je pokazivala vrijednosti MIC90 od 0,5 g/ml.
Clostridium tetani toxoid ............................................................................................................. ≥ 30 IU
Clostridium tetani toksoid ............................................................................................................ ≥ 30 IU
clotting of an artificial kidney
zgrušavanje u dijalizatoru
Clotting tests [e.g., prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT)] are affected as expected by the mechanism of action of apixaban.
Mehanizam djelovanja apiksabana očekivano utječe na rezultate testova zgrušavanja [npr., protrombinsko vrijeme (PV), INR i aktivirano parcijalno tromboplastinsko vrijeme (aPTV)].
cloudiness of the eye surface (transient corneal opacity) yellowing of the skin or whites of the eyes (jaundice).
zamagljenost površine oka (prolazna zamućenost rožnice) žutilo kože ili bjeloočnica (žutica).
clouding of the lens (cataract)
zamućenje leće (katarakta)
clouding of the lens due to injury (traumatic cataract)
zamućenje leće zbog ozljede (traumatska mrena)
clouding of the lens due to injury (traumatic cataract),
zamućenje leće zbog ozljede (traumatska mrena)
Clouding of the lens of the eye.
zamućenje leće u oku.
Clouding of your eye (cataract)
zamućenje oka (katarakta)
cloudy area in the lens of the eye (cataracts),
zamućeno područje u očnoj leći (katarakte),
Cloudy eyes
Zamućenje vida
cloudy lens in the eye (cataract)
zamućenje očne leće (katarakta)
Clozapine
Rapamicin
clozapine (used to treat psychiatric disorders such as schizophrenia),
klozapin (koristi se za liječenje psihijatrijskih poremećaja poput shizofrenije),
clozapine - used for some mental health problems
klozapin - koristi se za neke tegobe s psihičkim zdravljem
Clozapine Haloperidol Chlorpromazine Mesoridazine Phenothiazines Sertindole Sultopride Thioridazine Ziprasidone (saquinavir/ritonavir)
Klozapin Haloperidol Klorpromazin Mesoridazin Fenotiazin Sertindol Sultoprid Tioridazin Ziprazidon (sakvinavir/ritonavir)
clozapine, pimozide, (used to treat abnormal thoughts or feelings);
klozapin, pimozid (koriste se za liječenje nenormalnih misli ili osjećaja);
CLRENAL
CLBUBREŽNI
CLrenal (ml/min)
CLbubrežni (ml/min)
Clumps, non-uniform solution
Grudice, nejednolika otopina
Clumsiness and lack of coordination affecting balance, walking, limb or eye movements, or speech.
Nespretnost i nekoordiniranost pokreta, što uključuje poremećaj ravnoteže, hoda, pokreta udova ili očiju, odnosno nerazgovijetnost govora.
Clumsiness;
Nespretnost;
Cmax
0,93
Cmax
1,43
Cmax
NP
Cmax (IU/dL)
Cmaks (IU/dl)
Cmax (ng/mL)
apiksaban Cmax (ng/mL)
Cmax (ng/ml)
Cmax: (ng/ml)
Cmax (ng/ml) mean (S.D.), range
Cmax (ng/ml) srednja vrijednost (S.D.), raspon
Cmax (peak, g/l)
Cmax (najviše, g/l)
Cmax (pg/ml)
AUC (pg.sat/ml)
Cmax (µg/ml)
Cmax
Cmax (μg/mL) Mean ± SD
Cmax (μg/ml) Srednja vrijednost ± SD
Cmax 0.13 (0.09, 0.19)
Cmax 0,13 (0,09; 0,19)
Cmax 0.14 (0.11-0.18)
Cmax 0,14 (0,11-0,18)
Cmax 0.47 (0.41-0.52)
Cmax 0,47 (0,41-0,52)
Cmax 0.53 (0.37, 0.76)
Cmax 0,53 (0,37; 0,76)
Cmax 0.55 (0.41, 0.73)
Cmax 0,55 (0,41; 0,73)
Cmax 0.57 (0.40, 0.83)
Cmax 0,57 (0,40; 0,83)
Cmax 0.58 (0.42, 0.82)
Cmax 0,58 (0,42; 0,82)
Cmax 0.58 (0.52-0.66)
Cmax 0,58 (0,52-0,66)
Cmax 0.60 (0.52, 0.69)
Cmax 0,60 (0,52; 0,69)
Cmax 0.60 (0.56-0.64)
Cmax 0,60 (0,56-0,64)
Cmax 0.64 (0.44, 0.93)
Cmax 0,64 (0,44; 0,93)
Cmax 0.64 (0.61-0.67)
Cmax 0,64 (0,61-0,67)
Cmax 0.65 (0.59-0.70)
Maravirok: C12  4,74
Cmax 0.67 (0.63-0.71)
Amprenavir: Cmax  0,66
Cmax 0.68 (0.60-0.77)
Cmax 0,68 (0,60-0,77)
Cmax 0.70 (0.65-0.76)
Cmax 0,70 (0,65-0,76)
Cmax 0.71 (0.66-0.76)
Cmax 0,71 (0,66-0,76)
Cmax 0.72 (0.57, 0.92)
Cmax 0,72 (0,57; 0,92)
Cmax 0.74 (0.67, 0.82)
Cmax 0,74 (0,67; 0,82)
Cmax 0.74 (0.68-0.80)
Cmax 0,74 (0,68-0,80)
Cmax 0.76 (0.40, 1.44)
Cmax 0,76 (0,40; 1,44)
Cmax 0.76 (0.68-0.85)
Cmax 0,76 (0,68-0,85)
Cmax 0.79 (0.70-0.90)
Cmax 0,79 (0,70-0,90)
Cmax 0.79 (0.74-0.84)
Cmax 0,79 (0,74-0,84)
Cmax 0.80 (0.69-0.93)
Cmax 0,80 (0,69-0,93)
Cmax 0.85 (0.62, 1.16)
Cmax 0,85 (0,62; 1,16)
Cmax 0.85 (0.66, 1.09)
Cmax 0,85 (0,66; 1,09)
Cmax 0.85 (0.67, 1.07)
Cmax 0,85 (0,67; 1,07)
Cmax 0.85 (0.73-0.98)
Cmax 0,85 (0,73-0,98)
Cmax 0.85 (0.81-0.89)
AUC 0,89 (0,86-0,93)
Cmax 0.86 (0.71, 1.04)
Cmax 0,86 (0,71; 1,04)
Cmax 0.86 (0.76-0.97)
Cmax 0,86 (0,76-0,97)
Cmax 0.87 (0.78, 0.96)
Cmax 0,87 (0,78; 0,96)
Cmax 0.88 (0.77, 1.00)
Cmax 0,88 (0,77; 1,00)
Cmax 0.89 (0.61, 1.29)
Cmax 0,89 (0,61; 1,29)
Cmax 0.89 (0.71, 1.11)
Cmax 0,89 (0,71; 1,11)
Cmax 0.90 (0.76, 1.07)
Cmax 0,90 (0,76; 1,07)
Cmax 0.90 (0.79-1.02)
Cmax 0,90 (0,79-1,02)
Cmax 0.90 (0.85, 0.97)
Cmax 0,90 (0,85; 0,97)
Cmax 0.92 (0.81, 1.06)
Cmax 0,92 (0,81; 1,06)
Cmax 0.93 (0.84, 1.03)
Cmax 0,93 (0,84; 1,03)
Cmax 0.93 (0.84-1.03)
Cmax 0,93 (0,84-1,03)
Cmax 0.94 (0.82, 1.08)
Cmax 0,94 (0,82; 1,08)
Cmax 0.95 (0.85, 1.05)
Cmax 1,12 (1,01; 1,24)
Cmax 0.95 (0.86-1.06)
Cmax 0,95 (0,86-1,06)
Cmax 0.96 (0.87-1.05)
Cmax 0,96 (0,87-1,05)
Cmax 0.96 (0.90, 1.02)
Cmax 0,96 (0,90; 1,02)
Cmax 0.96 (0.90, 1.02)
Entekavir
Cmax 0.97 (0.63, 1.50)
Cmax 0,97 (0,63; 1,50)
Cmax 0.97 (0.79-1.21)
Cmax 0,97 (0,79-1,21)
Cmax 0.97 (0.83, 1.14)
Cmax 0,97 (0,83; 1,14)
Cmax 0.97 (0.88, 1.08)
Cmax 0,97 (0,88; 1,08)
Cmax 0.97 (0.89, 1.05)
Cmax 0,97 (0,89; 1,05)
Cmax 0.97 (0.92-1.03)
Cmax 0,97 (0,92-1,03)
Cmax 0.99 (0.88, 1.10)
Cmax 0,99 (0,88; 1,10)
Cmax 1.01 (0.96-1.05)
Cmax 1,01 (0,96-1,05)
Cmax 1.02 (0.80-1.31)
Cmax 1,02 (0,80-1,31)
Cmax 1.02 (0.92, 1.13)
Cmax 1,02 (0,92; 1,13)
Cmax 1.02 (0.92, 1.14)
Cmax 1,02 (0,92; 1,14)
Cmax 1.02 (0.93, 1.11)
Cmax 1,02 (0,93; 1,11)
Cmax 1.02 (0.95, 1.08)
Cmax 1,02 (0,95; 1,08)
Cmax 1.02 (0.96, 1.08)
Cmax 0,96 (0,90; 1,02)
Cmax 1.03 (0.96, 1.11)
Cmax 1,03 (0,96; 1,11)
Cmax 1.03 (0.99, 1.08)
Cmax 1,03 (0,99; 1,08)
Cmax 1.04 (0.99, 1.09)
Cmax 1,04 (0,99; 1,09)
Cmax 1.05 (1.00, 1.10)
Cmax 1,05 (1,00; 1,10)
Cmax 1.07 (0.83, 1.37)
Cmax 1,07 (0,83; 1,37)
Cmax 1.07 (0.88, 1.29)
Cmax 1,07 (0,88; 1,29)
Cmax 1.07 (0.95, 1.20)
Cmax 1,07 (0,95; 1,20)
Cmax 1.07 (0.97, 1.17)
Cmax 1,07 (0,97; 1,17)
Cmax 1.07 (0.98, 1.16)
Cmax 1,07 (0,98; 1,16)
Cmax 1.07 (0.98-1.16)
Cmax 1,07 (0,98-1,16)
Cmax 1.07 (0.99, 1.16)
Cmax 1,07 (0,99; 1,16)
Cmax 1.09 (0.83, 1.44)
Cmax 1,09 (0,83; 1,44)
Cmax 1.09 (0.95, 1.25)
Cmax 1,09 (0,95; 1,25)
Cmax 1.09 (0.98-1.21)
Cmax 1,09 (0,98-1,21)
Cmax 1.10 (0.89, 1.37)
Cmax 1,10 (0,89; 1,37)
Cmax 1.10 (0.96, 1.25)
Cmax 1,10 (0,96; 1,25)
Cmax 1.11 (0.98, 1.26)
Cmax 1,11 (0,98; 1,26)
Cmax 1.11 (0.99, 1.26)
Cmax 1,11 (0,99; 1,26)
Cmax 1.12 (1.01, 1.24)
Cmax 1,02 (0,96; 1,08)
Cmax 1.13 (0.77, 1.65)
Cmax 1,13 (0,77; 1,65)
Cmax 1.13 (0.77, 1.67)
Cmax 1,13 (0,77; 1,67)
Cmax 1.13 (0.87, 1.46)
Cmax 1,13 (0,87; 1,46)
Cmax 1.14 (0.95, 1.36)
Cmax 1,14 (1,04; 1,25)
Cmax 1.14 (1.04, 1.25)
Cmax 0,78 (0,51; 1,18)
Cmax 1.15 (1.07, 1.25)
Cmax 1,15 (1,07; 1,25)
Cmax 1.22 (1.05, 1.40)
Cmax 1,22 (1,05; 1,40)
Cmax 1.23 (1.14-1.33)
Cmax 1,23 (1,14-1,33)
Cmax 1.24 (1.10-1.41)
AUC 1,62 (1,45-1,81)
Cmax 1.25 (1.14, 1.37)
Cmax 1,25 (1,14; 1,37)
Cmax 1.25 (1.16, 1.35)
Cmax 1,25 (1,16; 1,35)
Cmax 1.26 (0.97-1.62)
Cmax 1,26 (0,97-1,62)
Cmax 1.27 (1.09-1.47)
Cmax 1,27 (1,09-1,47)
Cmax 1.27 (1.21-1.33)
Cmax 1,27 (1,21-1,33)
Cmax 1.29 (1.00, 1.66)
Cmax 1,29 (1,00; 1,66)
Cmax 1.29 (1.06, 1.58)
Cmax 1,29 (1,06; 1,58)
Cmax 1.30 (1.16-1.45)
Cmax 1,30 (1,16-1,45)
Cmax 1.32 (1.08-1.60)
Cmax 1,32 (1,08-1,60)
Cmax 1.34 (1.10, 1.62)
Cmax 1,34 (1,10; 1,62)
Cmax 1.39 (1.29, 1.50)
Cmax 1,39 (1,29; 1,50)
Cmax 1.41 (1.18, 1.68)
Cmax 1,41 (1,18; 1,68)
Cmax 1.42 (1.00, 2.03)
Cmax 1,42 (1,00; 2,03)
Cmax 1.46 (0.78, 2.73)
Cmax 1,46 (0,78; 2,73)
Cmax 1.47 (1.32, 1.63)
Cmax 1,47 (1,32; 1,63)
Cmax 1.49 (1.20-1.84)
Cmax 1,49 (1,20-1,84)
Cmax 1.50 (1.36-1.65) effect on P-gp transport in the gut
Cmax 1,50 (1,36-1,65) učinak na P-gp transport u crijevima
Cmax 1.67 (1.36, 2.05)
AUC 10,58 (7,78; 14,39)
Cmax 1.75 (1.51-2.03)
Cmax 1,75 (1,51-2,03)
Cmax 1.91 (1.77, 2.05)
Cmax 1,91 (1,77; 2,05)
Cmax 1.95 (1.84, 2.07)
Cmax 1,95 (1,84; 2,07)
Cmax 10.6 (8.74-12.85)
Cmax 10,6 (8,74-12,85)
Cmax 10.94 (8.92, 13.43)
Cmax 10,94 (8,92; 13,43)
Cmax 17.00 (12.94, 22.34)
Cmax 17,00 (12,94; 22,34)
Cmax 2.27 (1.72, 2.99)
Cmax 2,27 (1,72; 2,99)
Cmax 2.86 (2.52-3.25)
Cmax 2,86 (2,52-3,25)
Cmax 2.87 (2.29, 3.58)
Cmax 2,87 (2,29; 3,58)
Cmax 4.15 (3.46, 4.97)
elvitegravirom/kobicistatom/
Cmax 4.25 (3.25, 5.56)
Cmax 4,25 (3,25; 5,56)
Cmax 4.59 (3.70, 5.69)
AUC 5,36 (4,48; 6,43)
Cmax 5.27 (4.04, 6.86)
Cmax 5,27 (4,04; 6,86)
Cmax 5.49 (4.29, 7.04)
Cmax 5,49 (4,29; 7,04)
Cmax 5.66 (3.39, 9.45)
Cmax 5,66 (3,39; 9,45)
Cmax 6.52 (5.16, 8.24)
Cmax 6,52 (5,16; 8,24)
Cmax 7.31 (5.65, 9.45)
Cmax 7,31 (5,65; 9,45)
Cmax 7.81 (5.92-10.32)
Cmax 7,81 (5,92-10,32)
Cmax 9.35 (6.73-13.0)**
Cmax 9,35 (6,73-13,0)
Cmax : ↑ 1.8-fold
Cmax: ↑ 1,8 puta
Cmax achieved on dosing with 30-minute intravenous infusion of 6 mg/kg once daily in patients with normal renal function.
No Observed Effect Level, NOEL), uz Cmax dosegnut doziranjem od 6 mg/kg jedanput na dan putem 30-minutne intravenske infuzije u bolesnika s urednom funkcijom bubrega.
Cmax after a 10-minute infusion of 6 and 12 mg/m2 body surface area in the target population is approximately 1.5 and 3.5 µg/ml, respectively.
Cmax nakon infuzije od 6 i 12 mg/m2 tjelesne površine u trajanju od 10 minuta u ciljne populacije iznosi 1,5 odnosno 3,5 µg/ml.
Cmax and AUC (0–tlast) after inhalation of 5 microgram iloprost administered as Ventavis
Cmax i AUC (0-tlast) nakon inhalacije 5 mikrograma iloprosta primjenom lijeka Ventavis